WO2007059202A3 - Derives de pyrazolyluree utilisables dans le traitement du cancer - Google Patents

Derives de pyrazolyluree utilisables dans le traitement du cancer Download PDF

Info

Publication number
WO2007059202A3
WO2007059202A3 PCT/US2006/044322 US2006044322W WO2007059202A3 WO 2007059202 A3 WO2007059202 A3 WO 2007059202A3 US 2006044322 W US2006044322 W US 2006044322W WO 2007059202 A3 WO2007059202 A3 WO 2007059202A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
urea derivatives
derivatives useful
pyrazolyl urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/044322
Other languages
English (en)
Other versions
WO2007059202A2 (fr
Inventor
Louis-David Cantin
Roger Smith
Zhi Chen
Holia N Hatoum-Mokdad
Eric Mull
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Priority to EP06837652A priority Critical patent/EP1960394A2/fr
Priority to CA002629468A priority patent/CA2629468A1/fr
Publication of WO2007059202A2 publication Critical patent/WO2007059202A2/fr
Publication of WO2007059202A3 publication Critical patent/WO2007059202A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés de pyrazole urée, des compositions pharmaceutiques qui les contiennent et des procédés de traitement du cancer qui les utilisent.
PCT/US2006/044322 2005-11-15 2006-11-15 Derives de pyrazolyluree utilisables dans le traitement du cancer Ceased WO2007059202A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06837652A EP1960394A2 (fr) 2005-11-15 2006-11-15 Derives de pyrazolyluree utilisables dans le traitement du cancer
CA002629468A CA2629468A1 (fr) 2005-11-15 2006-11-15 Derives de pyrazolyluree utilisables dans le traitement du cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73640005P 2005-11-15 2005-11-15
US60/736,400 2005-11-15

Publications (2)

Publication Number Publication Date
WO2007059202A2 WO2007059202A2 (fr) 2007-05-24
WO2007059202A3 true WO2007059202A3 (fr) 2007-08-09

Family

ID=38016517

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/044322 Ceased WO2007059202A2 (fr) 2005-11-15 2006-11-15 Derives de pyrazolyluree utilisables dans le traitement du cancer

Country Status (3)

Country Link
EP (1) EP1960394A2 (fr)
CA (1) CA2629468A1 (fr)
WO (1) WO2007059202A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9242960B2 (en) 2009-04-03 2016-01-26 Respivert, Ltd. P38MAP kinase inhibitors

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006029795A1 (de) * 2006-06-27 2008-01-03 Schebo Biotech Ag Neue Harnstoff-Derivate und deren Verwendungen
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
JP2012504591A (ja) 2008-10-02 2012-02-23 レスピバート・リミテツド ｐ３８ＭＡＰキナーゼ阻害剤
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
MX2011006219A (es) * 2008-12-11 2011-06-28 Respivert Ltd Inhibidores de la proteina cinasa activada por el mitogeno p38.
WO2010089773A2 (fr) * 2009-02-02 2010-08-12 Indoco Remedies Limited Procédé pour la préparation de dérivés de nitropyridine
JP5760010B2 (ja) 2010-02-01 2015-08-05 キャンサー・リサーチ・テクノロジー・リミテッド １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
CA2835835C (fr) 2011-05-13 2019-04-02 Array Biopharma Inc. Composes de pyrrolidinyle-uree et de pyrrolidinyle thiouree en tant qu'inhibiteurs de kinase trka
WO2014078378A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-pyrrolidinyle urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
RS55593B1 (sr) * 2012-11-13 2017-06-30 Array Biopharma Inc Jedinjenja biciklične uree, tiouree, guanidina i cijanoguanidina korisna za lečenje bola
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078325A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-aryle monocycliques, n'-pyrazolyl-urée, thiourée, guanidine et cyanoguanidine utiles comme inhibiteurs de trka kinase
MX374242B (es) 2012-11-13 2025-03-05 Array Biopharma Inc Compuestos de n-pirrolidinil, n' -pirazolil-urea, tiourea, guanidina y cianoguanidina como inhibidores de trka cinasa.
WO2014078331A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-(arylalkyle)-n'-pyrazolyle-urée, de thiourée, de guanidine et de cyanoguanidine en tant qu'inhibiteurs de la kinase trka
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078372A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-pyrrolidinyle urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
WO2014078417A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de pyrazolylurée, d'urée, de thiourée, de guanidine et de cyanoguianidine en tant qu'inhibiteurs de la trka kinase
WO2014078328A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-pyrrolidinyle, n'-pyrazolyl-urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
MA40434B1 (fr) 2014-05-15 2019-09-30 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorophényl)-1-(2-méthoxyéthyl)pyrrolidin-3-yl)-3-(4-méthyl-3-(2-méthylpyrimidin-5-yl)-1-phényl-1h-pyrazol-5-yl)urée comme inhibiteur de la kinase trka
JP6864953B2 (ja) 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ａｘｌに対するヒトモノクローナル抗体
WO2016135041A1 (fr) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
CN107056653B (zh) * 2017-06-09 2019-07-09 丽珠医药集团股份有限公司 布南色林中间体对氟苯甲酰乙腈的合成方法
CA3140017A1 (fr) 2019-07-19 2021-01-28 Aurore HICK Derives d'uree polyaromatiques et leur utilisation dans le traitement de maladies musculaires
EP4029501A1 (fr) 2021-01-19 2022-07-20 Anagenesis Biotechnologies Combinaison de dérivés polyaromatiques de l'urée et d'inhibiteur glucocorticoïde ou hdac pour le traitement de maladies ou d'affections associées aux cellules musculaires et/ou aux cellules satellites

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032455A1 (fr) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition de raf kinase a l'aide d'urees heterocycliques aryle et heteroaryle substituees
WO1999032106A1 (fr) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition de raf kinase au moyen d'urees heterocycliques substituees
WO2005110994A2 (fr) * 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Derives de pyrazolyl uree substitues utiles dans le traitement du cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032455A1 (fr) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition de raf kinase a l'aide d'urees heterocycliques aryle et heteroaryle substituees
WO1999032106A1 (fr) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition de raf kinase au moyen d'urees heterocycliques substituees
WO2005110994A2 (fr) * 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Derives de pyrazolyl uree substitues utiles dans le traitement du cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JACQUES DUMAS, HOLIA HATOUM-MOKDAD, ROBERT N. SIBLEY, ROGER A. SMITH, WILLIAM J. SCOTT, UDAY KHIRE, WENDY LEE ET AL.: "Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, 2002, pages 1559 - 1562, XP002434053 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9242960B2 (en) 2009-04-03 2016-01-26 Respivert, Ltd. P38MAP kinase inhibitors

Also Published As

Publication number Publication date
EP1960394A2 (fr) 2008-08-27
CA2629468A1 (fr) 2007-05-24
WO2007059202A2 (fr) 2007-05-24

Similar Documents

Publication Publication Date Title
WO2007064872A3 (fr) Composes de l'uree utilises dans le traitement du cancer
WO2007059202A3 (fr) Derives de pyrazolyluree utilisables dans le traitement du cancer
WO2005110994A8 (fr) Derives de pyrazolyl uree substitues utiles dans le traitement du cancer
WO2007011962A3 (fr) Traitement du cancer
WO2008098104A8 (fr) Inhibiteurs de l'activité de akt
WO2005048948A3 (fr) Derives d'uree en tant que modulateurs de la kinase
WO2006102504A3 (fr) Combinaisons destinees au traitement de cancer
ZA200805163B (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
WO2007146965A3 (fr) Composés destinés au traitement d'une maladie périodontale
WO2007076423A3 (fr) INHIBITEURS D’ACTIVITE Akt
AP2005003452A0 (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.
WO2006086562A3 (fr) Derives de phenylazetidinone
WO2007044084A3 (fr) Inhibiteurs heterocycliques de mek et leurs procedes d'utilisation
WO2006083971A3 (fr) Anticorps dr5 et utilisations de ceux-ci
WO2008030883A3 (fr) Traitement du cancer
IL191938A (en) The ovarian heterocellular compounds, pharmaceuticals containing them, and the ovarian heterocellular compounds for cancer treatment
WO2008021368A3 (fr) Compositions et méthodes de neuroprotection
TNSN07322A1 (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
WO2007079164A3 (fr) Inhibiteurs de protéines kinases
EP2023926A4 (fr) Dérivés de pyridonecarboxamide utiles pour traiter des troubles hyperprolifératifs et liés à l'angiogenèse
WO2007067781A3 (fr) Inhibiteurs de proteines kinases
WO2007059008A3 (fr) Indenoisoquinolines n-substituees et leur synthese
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
WO2007064945A3 (fr) Therapies contre le cancer et compositions pharmaceutiques utilisees dans ces therapies
WO2007146335A3 (fr) Composés et compositions pour le traitement du cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2629468

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008541303

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006837652

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06837652

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: JP